Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

Related Articles by Review for PubMed (Select 18378520)

1.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

2.

Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

Baumhäkel M, Böhm M.

Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Review.

PMID:
19925045
3.

Telmisartan in high-risk cardiovascular patients.

Weber MA.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):36A-43A. doi: 10.1016/j.amjcard.2009.10.008. Review.

PMID:
20102972
4.

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

Unger T.

Am J Cardiol. 2003 May 22;91(10A):28G-34G. Review.

PMID:
12781906
5.

Telmisartan for the management of patients at high cardiovascular risk.

Ruilope LM.

Curr Med Res Opin. 2011 Aug;27(8):1673-82. doi: 10.1185/03007995.2011.597378. Epub 2011 Jun 30. Review.

PMID:
21718097
6.

Recent advances in cardiovascular risk reduction: implications of ONTARGET.

Guthrie R.

Clin Cornerstone. 2009;9 Suppl 3:S18-26. Review.

PMID:
19409352
8.

Renin-angiotensin system blockade and cardiovascular and renal protection.

Hoogwerf BJ.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):30A-5A. doi: 10.1016/j.amjcard.2009.10.009. Review.

PMID:
20102971
9.

From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.

Böhm M, Baumhäkel M, Mahfoud F, Werner C.

Cardiology. 2010;117(3):163-73. doi: 10.1159/000320094. Epub 2010 Nov 4. Review.

PMID:
21051889
10.

[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].

Oğuz A.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 6:4-12. Review. Turkish.

PMID:
20019467
11.

Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Drugs. 2002;62(9):1381-405. Review.

PMID:
12076194
12.

Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.

Wang JG, Pimenta E, Chwallek F.

Vasc Health Risk Manag. 2014 Apr 5;10:189-200. doi: 10.2147/VHRM.S59429. eCollection 2014. Review.

13.

Telmisartan: a review of its use in cardiovascular disease prevention.

Frampton JE.

Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-000000000-00000. Review.

PMID:
21504246
14.

Clinical trial update: focus on the ONTARGET study.

Fitchett D.

Vasc Health Risk Manag. 2007;3(6):901-8. Review.

15.

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):151-61. doi: 10.1586/ecp.10.141. Review.

PMID:
22115399
16.
17.
18.

Spotlight on ramipril in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Am J Cardiovasc Drugs. 2003;3(2):113-6. Review.

PMID:
14727938
19.

Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.

Diener HC.

J Hypertens Suppl. 2009 Jul;27(5):S31-6. doi: 10.1097/01.hjh.0000357906.60778.7f. Review.

PMID:
19587553
20.

Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.

Zou Z, Xi GL, Yuan HB, Zhu QF, Shi XY.

J Hum Hypertens. 2009 May;23(5):339-49. doi: 10.1038/jhh.2008.132. Epub 2008 Nov 6. Review.

PMID:
18987649
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk